AGAna Caroline Zimmer Gelatti

Ana Caroline Zimmer Gelatti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ana Caroline Zimmer Gelatti has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Brief Report: Clinical use, access, and awareness of the utility of ctDNA-based liquid biopsy for NSCLC among oncologists in Latin America – The OMEGA survey.

    by Vladmir C. Cordeiro de Lima, Erick F. Saldanha, Danielli Matias, Andres F. Cardona, Leonardo Gil-Santana, Clarissa Baldotto, Eldsamira Mascarenhas, Oscar Arrieta, Aline Fares, Milena Perez Mak, et al.

  • Treatment of ALK+ Non–Small Cell Lung Cancer in the Brazilian Public and Private Health Care Systems: A Tale of Inequalities (LACOG/GBOT 1918)

    by Eldsamira Mascarenhas, Ana C. Z. Gelatti, Tatiane Montella, Marcelo Corassa, William N. William, Rosely Yamamura, Clarissa Baldotto, Eduardo H. Cronemberger, Aknar F. C. Calabrich, Giuliano S. Borges, et al.

    PURPOSE: ALK rearrangements occur in 5.4% of Brazilian patients with non–small cell lung cancer (NSCLC). Data on treatment patterns, access to ALK inhibitors, and survival outcomes are scarce. MATERIALS AND METHODS: LACOG/GBOT 1918 is a retrospective, observational study that included patients diagnosed with ALK-positive NSCLC between January 2015 and December 2020 in 12 Brazilian public and private centers. Data were extracted from patient records, including clinic-epidemiologic features, diagnosis, ALK testing methods, treatment patterns, and outcomes. Data were analyzed using descriptive statistical methods. RESULTS: A total of 101 patients were enrolled. The median age was 55 years (range, 18-86), and 55.4% were female. Immunohistochemistry was the most frequently used method for ALK testing. The median time from the first symptom to diagnosis was 2 months, from diagnosis to ALK testing 1.7 months, and from diagnosis to treatment initiation 1.7 months. Among patients receiving first-line treatment, only 47.9% received ALK inhibitors (53.9% private v 22.2% public), with crizotinib being the most used. For second-line treatment, 66.0% of patients received ALK inhibitors, with alectinib being the most used (50%). Most treated patients had access to ALK inhibitors in some line of treatment (83.3% private v 72.2% public); however, in the public setting, targeted treatment was restricted to first-generation and second-generation ALK inhibitors. The 3-year overall survival (OS) rate was 82.6% (95% CI, 72.6 to 89.2), with a lower 3-year OS in the public setting (61.4% public v 87.2% private; P = .0279). CONCLUSION: Access to targeted ALK therapy is limited in the public health care system, reflecting poor clinical outcomes. Public health measures are necessary to minimize the differences between these two systems.

  • Open Access

    Current Access to Anaplastic Lymphoma Kinase Testing and Targeted Therapies for Non–Small Cell Lung Cancer in Brazil: Results From a Cross-Sectional Survey (LACOG 1224-GBOT)

    by Eldsamira Mascarenhas, Clarissa Baldotto, Ana Caroline Z. Gelatti, Carlos Henrique A. Teixeira, Taiane F. Rebelatto, Caio de A. Monteiro, Rafaela G. de Jesus, Vladmir C. Cordeiro de Lima

    PURPOSE: In Brazil, diagnosing and treating non–small cell lung cancer (NSCLC) with actionable molecular alterations pose substantial challenges because of health care disparities. Anaplastic lymphoma kinase (ALK) rearrangements represent a clinically relevant subset with highly effective targeted therapies. However, real-world access to ALK diagnostics and treatments across different Brazilian health care sectors remains inadequately characterized. METHODS: We conducted a cross-sectional survey of Brazilian oncologists between October 2024 and March 2025 to assess the availability of ALK testing and targeted therapies, alongside perceived implementation barriers. Of 197 responses collected, 156 were included in the final analytic cohort. Data were analyzed using descriptive statistics, and categorical variables were reported as proportions with 95% CIs. RESULTS: Within the final analytic cohort (N = 156), 93.9% of the respondents practicing in the private sector (n = 147) reported access to ALK testing, whereas only 43.9% of those practicing in the public health care system (n = 107) had access. Access to ALK-targeted therapies was limited for the public health care population: 7.1% received crizotinib and <2% received newer-generation ALK-targeted therapies available in the first-line setting. By contrast, in the private sector, 75.6% and 60.9% reported access to alectinib and lorlatinib, respectively. Chemotherapy remained predominant in the public health care system. Main barriers included lack of reimbursement (58.3%), insufficient tissue (40.4%), and urgency to initiate treatment (36.5%). CONCLUSION: Despite robust evidence supporting ALK-targeted therapies, this study highlights substantial disparities in access to diagnostics and treatment for ALK-rearranged NSCLC in Brazil, particularly among patients reliant on the public health care system. Findings underscore the need for policies to strengthen testing infrastructure, ensure equitable access to guideline-recommended therapies, and enhance provider education. Addressing these gaps is essential for equitable precision oncology and improved outcomes.

  • Lung Cancer in Women in Brazil: Incidence, Trends, and Overlooked Risk Factors

    by Eldsamira Mascarenhas, Cinthya Sternberg, Sofia Vidaurre, Ellen Nascimento, Camila Greggianin, Lilian Faroni, Tercia Reis, Ana Caroline Gelatti, Clarissa Baldotto

    Lung cancer (LC) incidence and mortality rates are increasing in Brazil, particularly among women. Studies indicate that sex may affect incidence, survival, and treatment response. However, overlooked or unknown risk factors may also play a role in the sex disparities observed. For instance, although smoking is a major risk factor for LC, increasing rates of LC among nonsmoking women in Brazil, and elsewhere, have been observed. Also, traditional gender roles expose women to specific environmental hazards, as they are often expected to perform domestic tasks and thus are more likely to be indoors and exposed to second-hand smoke, air pollution from cooking fuels, and radon. In addition, occupational hazards such as formaldehyde, particularly in hairdressing, disproportionately affect women. This narrative review highlights the disparities associated with LC and female sex in Brazil, and calls for more research on these overlooked risk factors.

  • Gender Equity and Workplace Mistreatment in Oncology: Results From a Survey by the Brazilian Society of Clinical Oncology

    by Daniele Assad Suzuki, Maria de Fatima Dias Gaui, Daniela Dornelles Rosa, Karime Kalil Machado, Fernanda Cesar Moura, Ana Caroline Zimmer Gelatti, Maria Ignez Freitas Melro Braghiroli, Renata Costa Cangussu, Eldsamira Mascarenhas, Angelica Nogueira-Rodrigues, et al.

    PURPOSE: There are no available data concerning gender equity and workplace mistreatment within the field of oncology in Brazil. The Brazilian Society of Clinical Oncology (Sociedade Brasileira de Oncologia Clínica [SBOC]) performed a survey study to present and discuss this subject and gain insights into strategies that would mitigate gender inequities. MATERIALS AND METHODS: A 24-question survey in Portuguese, assessing demographics, professional context, achievements, workplace mistreatment, parenthood, and gender balance in the workplace, was developed and administered by the SBOC Women's Leadership Committee. SBOC members were invited to participate by e-mail. RESULTS: Among the 2,125 SBOC members, 146 women (72%) and 56 men (28%) participated in the survey. Approximately 87.5% of men versus 65.5% of women believed that they had equal rights ( P < .002) at their workplace. Chiefs of oncology departments were more often men than women (30.4% v 13.7%, P < .006). Furthermore, 60.8% of men versus 85.1% of women ( P = .0003) believed that a specific workplace guideline regarding gender equity should exist. Only 29.5% of women versus 98.2% of men ( P < .0001) believed that they did not experience gender discrimination throughout their careers. Approximately 50% of women versus 21% of men reported experiencing moral harassment at work ( P = .0002), whereas 24% of women and 7% of men reported sexual harassment ( P = .005). Multivariable logistic regression confirmed the significant results of univariable analysis when adjusted for age group and holding a department chief position. CONCLUSION: Our data show an alarming level of sexual and moral harassment and gender inequity experienced by SBOC members, highlighting the urgent need for programs to address these situations.


  • Open Access

    Durvalumab as consolidation therapy in patients who received chemoradiotherapy for unresectable stage III NSCLC: Real-world data from an expanded access program in Brazil (LACOG 0120)

    by Mauro Zukin, Victor Gondim, Andrea Kazumi Shimada, Ellias Magalhães E Abreu Lima, Clarissa Mathias, Williams Fernandes Barra, William Nassib William Junior, Mônica Padoan, Yuri Bittencourt, Rosely Yamamura, et al.

    Objective: The PACIFIC trial established standard therapy for patients with unresectable stage III NSCLC who did not progress after platinum-based concurrent chemoradiation therapy. However, real-world data, particularly from Latin America, remain limited. The LACOG 0120 study aimed to evaluate the efficacy and safety of consolidation therapy with durvalumab in a real-world setting in Brazil. Methods: Patients with unresectable stage III NSCLC who received chemoradiotherapy followed by durvalumab consolidation therapy through an expanded access program were evaluated. The primary objective was to assess progression-free survival (PFS). Secondary endpoints included overall survival (OS), treatment compliance, and safety, with a focus on the incidence and severity of immune-mediated adverse events (NCT04948411). Results: Thirty-one patients from seven centers were evaluated. Median follow-up was 50.3 months (95% CI: 48.6–54.4). Median PFS was 9.9 months (95% CI: 7.3–52.4), with a 36 month-PFS of 34.5% (95% CI: 17.7–52.1). Median OS was 34.9 months (95% CI: 26.0–NR), and the 36 month-OS was 46.3% (95% CI: 25.7–64.6). Durvalumab was administered for a median of 17 cycles (10 to 24), with 45.2% of patients completing the planned therapy. The main reason for discontinuation was disease progression. Treatment-related adverse events of any grade occurred in 12 patients (38.7%), with grade 3 events reported in two (6.5%). Pneumonitis was observed in 4 patients (12.9%) – grade 3 in 1 patient. Conclusions: PFS was lower in this analysis compared to the PACIFIC trial; however, OS was similar, indicating comparable efficacy in a real-world setting among Brazilian patients with unresectable stage III NSCLC. No new safety concerns were identified.


  • Open Access

    PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancer

    by Fabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, Kiyotaka Yoh, Ana Caroline Zimmer Gelatti, Helen Mann, Aarthi Gopinathan, Zofia Felicja Bielecka, Michael Newton, Charu Aggarwal

    Evidence from the Phase III PACIFIC trial established durvalumab, a monoclonal antibody (mAb) targeting PD-L1, following concurrent chemoradiotherapy (cCRT) as a global standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC). There remains an unmet need to improve upon the outcomes achieved with the PACIFIC regimen. Combining durvalumab with other immunotherapies may improve outcomes further. Two such immunotherapies include oleclumab, an mAb targeting CD73, and monalizumab, an mAb targeting NKG2A. Both agents demonstrated antitumor activity in early-phase trials. PACIFIC-9 (NCT05221840) is an international, double-blind, randomized, placebo-controlled, Phase III trial comparing durvalumab plus either oleclumab or monalizumab with durvalumab plus placebo in patients with unresectable, stage III NSCLC and no disease progression following cCRT.Clinical Trial Registration: NCT05221840 (ClinicalTrials.gov).


  • Open Access

    Lung Cancer and the COVID-19 pandemic: Recommendations from the Brazilian Thoracic Oncology Group

    by Clarissa Baldotto, Ana Gelatti, Arthur Accioly, Clarissa Mathias, Eldsamira Mascarenhas, Heloisa Carvalho, Lilian Faroni, Luiz Henrique Araújo, Mauro Zukin, Rafael Gadia, et al.

    New cases of the novel coronavirus disease 2019 (COVID-19), also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), continue to rise worldwide following the declaration of a pandemic by the World Health Organization (WHO). The current ...